主营介绍

  • 产品类型:

    西药制剂、原料药、中间体、中药制剂、诊断试剂、诊断设备

  • 产品名称:

    西药制剂 原料药 中间体 中药制剂 诊断试剂 诊断设备

  • 经营范围:

    生产和销售自产的中西原料药、医药中间体、中药材、中药饮片医疗器械、卫生材料、保健品、药用化妆品、中西成药、生化试剂,兼营化工、食品、信息业务,医药原料药、医疗诊断设备及试剂;药物新产品的研究和开发,技术成果转让;管理服务;医疗诊断设备的租赁;本企业自产产品及相关技术的进出口业务;批发中成药、化学原料药及其制剂、抗生素原料药及其制剂、生物制品(预防性生物制品除外)、生化药品。(涉及配额许可证、国家有专项规定的商品应按有关规定办理;需其他行政许可项目,取得许可后方可经营)

主营构成分析

{"2017-06-30":{"YYSR":{"1":[["\u4e2d\u836f\u5236\u5242","108425.87"],["\u539f\u6599\u836f\u548c\u4e2d\u95f4\u4f53","100368.02"],["\u4fc3\u6027\u6fc0\u7d20","66474.96"],["\u6d88\u5316\u9053","48320.60"],["\u5176\u4ed6","40251.42"],["\u5176\u4ed6\u4e1a\u52a1\u603b\u8ba1",61701.37]],"2":[["\u53c2\u82aa\u6276\u6b63\u6ce8\u5c04\u6db2","83510.65"]],"3":[["\u5883\u5185","379272.74"],["\u5883\u5916","46269.49"]]},"YYCB":{"1":[["\u4e2d\u836f\u5236\u5242","22493.49"],["\u539f\u6599\u836f\u548c\u4e2d\u95f4\u4f53","75711.16"],["\u4fc3\u6027\u6fc0\u7d20","22946.23"],["\u6d88\u5316\u9053","4000.24"],["\u5176\u4ed6","4314.69"],["\u5176\u4ed6\u4e1a\u52a1\u603b\u8ba1",19732.99]],"2":[["\u53c2\u82aa\u6276\u6b63\u6ce8\u5c04\u6db2","14876.21"]],"3":[["\u5883\u5185","114049.84"],["\u5883\u5916","35148.95"]]},"LRBL":{"1":[["\u4e2d\u836f\u5236\u5242","31.10"],["\u539f\u6599\u836f\u548c\u4e2d\u95f4\u4f53","8.92"],["\u4fc3\u6027\u6fc0\u7d20","15.75"],["\u6d88\u5316\u9053","16.04"],["\u5176\u4ed6","13.00"],["\u5176\u4ed6\u4e1a\u52a1\u603b\u8ba1",15.19]],"2":[["\u53c2\u82aa\u6276\u6b63\u6ce8\u5c04\u6db2","100.00"]],"3":[["\u5883\u5185","95.98"],["\u5883\u5916","4.02"]]}},"2016-12-31":{"YYSR":{"1":[["\u4e2d\u836f\u5236\u5242","212564.69"],["\u539f\u6599\u836f\u53ca\u4e2d\u95f4\u4f53","173573.12"],["\u897f\u836f\u5236\u5242-\u4fc3\u6027\u6fc0\u7d20","117993.21"],["\u897f\u836f\u5236\u5242-\u5176\u4ed6","73619.37"],["\u897f\u836f\u5236\u5242-\u6d88\u5316\u9053","71793.12"],["\u5176\u4ed6\u4e1a\u52a1\u603b\u8ba1",112123.16]],"2":[["\u53c2\u82aa\u6276\u6b63\u6ce8\u5c04\u6db2","167963.45"]],"3":[["\u5883\u5185","686734.43"],["\u5883\u5916","74932.24"]]},"YYCB":{"1":[["\u4e2d\u836f\u5236\u5242","42882.89"],["\u539f\u6599\u836f\u53ca\u4e2d\u95f4\u4f53","140206.21"],["\u897f\u836f\u5236\u5242-\u4fc3\u6027\u6fc0\u7d20",""],["\u897f\u836f\u5236\u5242-\u5176\u4ed6",""],["\u897f\u836f\u5236\u5242-\u6d88\u5316\u9053",""],["\u5176\u4ed6\u4e1a\u52a1\u603b\u8ba1",24690.6]],"2":[["\u53c2\u82aa\u6276\u6b63\u6ce8\u5c04\u6db2","26926.18"]],"3":[["\u5883\u5185","215054.01"],["\u5883\u5916",""]]},"LRBL":{"1":[["\u4e2d\u836f\u5236\u5242","72.16"],["\u539f\u6599\u836f\u53ca\u4e2d\u95f4\u4f53","14.19"],["\u897f\u836f\u5236\u5242-\u4fc3\u6027\u6fc0\u7d20",""],["\u897f\u836f\u5236\u5242-\u5176\u4ed6",""],["\u897f\u836f\u5236\u5242-\u6d88\u5316\u9053",""],["\u5176\u4ed6\u4e1a\u52a1\u603b\u8ba1",13.65]],"2":[["\u53c2\u82aa\u6276\u6b63\u6ce8\u5c04\u6db2","100.00"]],"3":[["\u5883\u5185","100.00"],["\u5883\u5916",""]]}},"2016-06-30":{"YYSR":{"1":[["\u897f\u836f\u5236\u5242","163742.66"],["\u4e2d\u836f\u5236\u5242","105001.31"],["\u539f\u6599\u836f\u548c\u4e2d\u95f4\u4f53","82156.23"],["\u8bca\u65ad\u8bd5\u5242\u53ca\u8bbe\u5907","26003.91"],["\u5176\u4ed6","142.54"]],"2":[["\u53c2\u82aa\u6276\u6b63\u6ce8\u5c04\u6db2","82283.76"]],"3":[["\u5883\u5185","342664.10"],["\u5883\u5916","34382.55"]]},"YYCB":{"1":[["\u897f\u836f\u5236\u5242","33748.30"],["\u4e2d\u836f\u5236\u5242","21967.95"],["\u539f\u6599\u836f\u548c\u4e2d\u95f4\u4f53","67328.74"],["\u8bca\u65ad\u8bd5\u5242\u53ca\u8bbe\u5907","11019.38"],["\u5176\u4ed6","422.74"]],"2":[["\u53c2\u82aa\u6276\u6b63\u6ce8\u5c04\u6db2","14168.61"]],"3":[["\u5883\u5185","107672.87"],["\u5883\u5916","26814.24"]]},"LRBL":{"1":[["\u897f\u836f\u5236\u5242","53.59"],["\u4e2d\u836f\u5236\u5242","34.23"],["\u539f\u6599\u836f\u548c\u4e2d\u95f4\u4f53","6.11"],["\u8bca\u65ad\u8bd5\u5242\u53ca\u8bbe\u5907","6.18"],["\u5176\u4ed6","-0.12"]],"2":[["\u53c2\u82aa\u6276\u6b63\u6ce8\u5c04\u6db2","100.00"]],"3":[["\u5883\u5185","96.88"],["\u5883\u5916","3.12"]]}}}
{"YYSR":{"chartWrap1":[{"name":"\u4e2d\u836f\u5236\u5242","timeData":["2017-06-30","2016-12-31","2016-06-30"],"lineData":[108425.87,212564.69,105001.31],"columnData":[25.48,27.91,27.85],"unit":["10.84\u4ebf","21.26\u4ebf","10.50\u4ebf"]},{"name":"\u539f\u6599\u836f\u548c\u4e2d\u95f4\u4f53","timeData":["2017-06-30","2016-06-30"],"lineData":[100368.02,82156.23],"columnData":[23.59,21.79],"unit":["10.04\u4ebf","8.22\u4ebf"]},{"name":"\u4fc3\u6027\u6fc0\u7d20","timeData":["2017-06-30"],"lineData":[66474.96],"columnData":[15.62],"unit":["6.65\u4ebf"]},{"name":"\u6d88\u5316\u9053","timeData":["2017-06-30"],"lineData":[48320.6],"columnData":[11.36],"unit":["4.83\u4ebf"]},{"name":"\u5176\u4ed6","timeData":["2017-06-30","2016-06-30"],"lineData":[40251.42,142.54],"columnData":[9.46,0.04],"unit":["4.03\u4ebf","142.54\u4e07"]},{"name":"\u5176\u4ed6\u4e1a\u52a1\u603b\u8ba1","timeData":["2017-06-30","2016-12-31"],"lineData":[61701.37,112123.16],"columnData":[14.5,14.73],"unit":["6.17\u4ebf","11.21\u4ebf"]},{"name":"\u539f\u6599\u836f\u53ca\u4e2d\u95f4\u4f53","timeData":["2016-12-31"],"lineData":[173573.12],"columnData":[22.79],"unit":["17.36\u4ebf"]},{"name":"\u897f\u836f\u5236\u5242-\u4fc3\u6027\u6fc0\u7d20","timeData":["2016-12-31"],"lineData":[117993.21],"columnData":[15.49],"unit":["11.80\u4ebf"]},{"name":"\u897f\u836f\u5236\u5242-\u5176\u4ed6","timeData":["2016-12-31"],"lineData":[73619.37],"columnData":[9.67],"unit":["7.36\u4ebf"]},{"name":"\u897f\u836f\u5236\u5242-\u6d88\u5316\u9053","timeData":["2016-12-31"],"lineData":[71793.12],"columnData":[9.43],"unit":["7.18\u4ebf"]},{"name":"\u897f\u836f\u5236\u5242","timeData":["2016-06-30"],"lineData":[163742.66],"columnData":[43.43],"unit":["16.37\u4ebf"]},{"name":"\u8bca\u65ad\u8bd5\u5242\u53ca\u8bbe\u5907","timeData":["2016-06-30"],"lineData":[26003.91],"columnData":[6.9],"unit":["2.60\u4ebf"]}],"chartWrap2":[{"name":"\u53c2\u82aa\u6276\u6b63\u6ce8\u5c04\u6db2","timeData":["2017-06-30","2016-12-31","2016-06-30"],"lineData":[83510.65,167963.45,82283.76],"columnData":[100,100,100],"unit":["8.35\u4ebf","16.80\u4ebf","8.23\u4ebf"]}],"chartWrap3":[{"name":"\u5883\u5185","timeData":["2017-06-30","2016-12-31","2016-06-30"],"lineData":[379272.74,686734.43,342664.1],"columnData":[89.13,90.16,90.88],"unit":["37.93\u4ebf","68.67\u4ebf","34.27\u4ebf"]},{"name":"\u5883\u5916","timeData":["2017-06-30","2016-12-31","2016-06-30"],"lineData":[46269.49,74932.24,34382.55],"columnData":[10.87,9.84,9.12],"unit":["4.63\u4ebf","7.49\u4ebf","3.44\u4ebf"]}]},"YYCB":{"chartWrap1":[{"name":"\u4e2d\u836f\u5236\u5242","timeData":["2017-06-30","2016-12-31","2016-06-30"],"lineData":[22493.49,42882.89,21967.95],"columnData":[15.08,20.64,16.33],"unit":["2.25\u4ebf","4.29\u4ebf","2.20\u4ebf"]},{"name":"\u539f\u6599\u836f\u548c\u4e2d\u95f4\u4f53","timeData":["2017-06-30","2016-06-30"],"lineData":[75711.16,67328.74],"columnData":[50.75,50.06],"unit":["7.57\u4ebf","6.73\u4ebf"]},{"name":"\u4fc3\u6027\u6fc0\u7d20","timeData":["2017-06-30"],"lineData":[22946.23],"columnData":[15.38],"unit":["2.29\u4ebf"]},{"name":"\u6d88\u5316\u9053","timeData":["2017-06-30"],"lineData":[4000.24],"columnData":[2.68],"unit":["4000.24\u4e07"]},{"name":"\u5176\u4ed6","timeData":["2017-06-30","2016-06-30"],"lineData":[4314.69,422.74],"columnData":[2.89,0.31],"unit":["4314.69\u4e07","422.74\u4e07"]},{"name":"\u5176\u4ed6\u4e1a\u52a1\u603b\u8ba1","timeData":["2017-06-30","2016-12-31"],"lineData":[19732.99,24690.6],"columnData":[13.23,11.88],"unit":["1.97\u4ebf","2.47\u4ebf"]},{"name":"\u539f\u6599\u836f\u53ca\u4e2d\u95f4\u4f53","timeData":["2016-12-31"],"lineData":[140206.21],"columnData":[67.48],"unit":["14.02\u4ebf"]},{"name":"\u897f\u836f\u5236\u5242-\u4fc3\u6027\u6fc0\u7d20","timeData":["2016-12-31"],"lineData":[0],"columnData":[0],"unit":["0.00"]},{"name":"\u897f\u836f\u5236\u5242-\u5176\u4ed6","timeData":["2016-12-31"],"lineData":[0],"columnData":[0],"unit":["0.00"]},{"name":"\u897f\u836f\u5236\u5242-\u6d88\u5316\u9053","timeData":["2016-12-31"],"lineData":[0],"columnData":[0],"unit":["0.00"]},{"name":"\u897f\u836f\u5236\u5242","timeData":["2016-06-30"],"lineData":[33748.3],"columnData":[25.09],"unit":["3.37\u4ebf"]},{"name":"\u8bca\u65ad\u8bd5\u5242\u53ca\u8bbe\u5907","timeData":["2016-06-30"],"lineData":[11019.38],"columnData":[8.19],"unit":["1.10\u4ebf"]}],"chartWrap2":[{"name":"\u53c2\u82aa\u6276\u6b63\u6ce8\u5c04\u6db2","timeData":["2017-06-30","2016-12-31","2016-06-30"],"lineData":[14876.21,26926.18,14168.61],"columnData":[100,100,100],"unit":["1.49\u4ebf","2.69\u4ebf","1.42\u4ebf"]}],"chartWrap3":[{"name":"\u5883\u5185","timeData":["2017-06-30","2016-12-31","2016-06-30"],"lineData":[114049.84,215054.01,107672.87],"columnData":[76.44,100,80.06],"unit":["11.40\u4ebf","21.51\u4ebf","10.77\u4ebf"]},{"name":"\u5883\u5916","timeData":["2017-06-30","2016-12-31","2016-06-30"],"lineData":[35148.95,0,26814.24],"columnData":[23.56,0,19.94],"unit":["3.51\u4ebf","0.00","2.68\u4ebf"]}]},"LRBL":{"chartWrap1":[{"name":"\u4e2d\u836f\u5236\u5242","timeData":["2017-06-30","2016-12-31","2016-06-30"],"lineData":[31.1,72.16,34.23],"columnData":[31.1,72.16,34.23],"unit":["31.10\u4e07","72.16\u4e07","34.23\u4e07"]},{"name":"\u539f\u6599\u836f\u548c\u4e2d\u95f4\u4f53","timeData":["2017-06-30","2016-06-30"],"lineData":[8.92,6.11],"columnData":[8.92,6.11],"unit":["8.92\u4e07","6.11\u4e07"]},{"name":"\u4fc3\u6027\u6fc0\u7d20","timeData":["2017-06-30"],"lineData":[15.75],"columnData":[15.75],"unit":["15.75\u4e07"]},{"name":"\u6d88\u5316\u9053","timeData":["2017-06-30"],"lineData":[16.04],"columnData":[16.04],"unit":["16.04\u4e07"]},{"name":"\u5176\u4ed6","timeData":["2017-06-30","2016-06-30"],"lineData":[13,-0.12],"columnData":[13,-0.12],"unit":["13.00\u4e07","-1200"]},{"name":"\u5176\u4ed6\u4e1a\u52a1\u603b\u8ba1","timeData":["2017-06-30","2016-12-31"],"lineData":[15.19,13.65],"columnData":[15.19,13.65],"unit":["15.19\u4e07","13.65\u4e07"]},{"name":"\u539f\u6599\u836f\u53ca\u4e2d\u95f4\u4f53","timeData":["2016-12-31"],"lineData":[14.19],"columnData":[14.19],"unit":["14.19\u4e07"]},{"name":"\u897f\u836f\u5236\u5242-\u4fc3\u6027\u6fc0\u7d20","timeData":["2016-12-31"],"lineData":[0],"columnData":[0],"unit":["0.00"]},{"name":"\u897f\u836f\u5236\u5242-\u5176\u4ed6","timeData":["2016-12-31"],"lineData":[0],"columnData":[0],"unit":["0.00"]},{"name":"\u897f\u836f\u5236\u5242-\u6d88\u5316\u9053","timeData":["2016-12-31"],"lineData":[0],"columnData":[0],"unit":["0.00"]},{"name":"\u897f\u836f\u5236\u5242","timeData":["2016-06-30"],"lineData":[53.59],"columnData":[53.59],"unit":["53.59\u4e07"]},{"name":"\u8bca\u65ad\u8bd5\u5242\u53ca\u8bbe\u5907","timeData":["2016-06-30"],"lineData":[6.18],"columnData":[6.18],"unit":["6.18\u4e07"]}],"chartWrap2":[{"name":"\u53c2\u82aa\u6276\u6b63\u6ce8\u5c04\u6db2","timeData":["2017-06-30","2016-12-31","2016-06-30"],"lineData":[100,100,100],"columnData":[100,100,100],"unit":["100.00\u4e07","100.00\u4e07","100.00\u4e07"]}],"chartWrap3":[{"name":"\u5883\u5185","timeData":["2017-06-30","2016-12-31","2016-06-30"],"lineData":[95.98,100,96.88],"columnData":[95.98,100,96.88],"unit":["95.98\u4e07","100.00\u4e07","96.88\u4e07"]},{"name":"\u5883\u5916","timeData":["2017-06-30","2016-12-31","2016-06-30"],"lineData":[4.02,0,3.12],"columnData":[4.02,0,3.12],"unit":["4.02\u4e07","0.00","3.12\u4e07"]}]}}

营业收入 X

单位(%) 单位(万元)
注:通常在中报、年报时披露 
业务名称 营业收入(元) 收入比例 营业成本(元) 成本比例 利润比例 毛利率
按行业 中药制剂 10.84亿 25.48% 2.25亿 15.08% 31.10% 79.25%
原料药和中间体 10.04亿 23.59% 7.57亿 50.75% 8.92% 24.57%
促性激素 6.65亿 15.62% 2.29亿 15.38% 15.75% 65.48%
消化道 4.83亿 11.36% 4000.24万 2.68% 16.04% 91.72%
其他 4.03亿 9.46% 4314.69万 2.89% 13.00% 89.28%
诊断试剂及设备 2.89亿 6.79% 1.25亿 8.40% 5.92% 56.60%
抗微生物药物 2.28亿 5.36% 5039.07万 3.38% 6.43% 77.91%
心脑血管 1.00亿 2.35% 2159.59万 1.45% 2.84% 78.44%
按产品 参芪扶正注射液 8.35亿 100.00% 1.49亿 100.00% 100.00% 82.19%
按地区 境内 37.93亿 89.13% 11.40亿 76.44% 95.98% 69.93%
境外 4.63亿 10.87% 3.51亿 23.56% 4.02% 24.03%

董事会经营评述

  一、概述
  2017年是医药企业机遇与挑战并存的一年。随着国家医疗体制改革不断深入,医保目录调整更新、药品审评速度加快、仿制药一致性评价持续推进、两票制深入实施等政策对医药行业的影响逐步体现。
  2017上半年,医药工业增速较2016年略有回升。国家统计局规模以上工业企业数据显示,2017上半年医药制造业全行业的主营业务收入同比增长12.6%,利润同比增长15.9%。
  本报告期,本集团实现营业收入人民币4,274.76百万元,相比上年同期的人民币3,784.30百万元,同比增长12.96%;实现净利润人民币550.39百万元,相比上年同期的人民币427.47百万元,同比增长28.7... 查看全部▼

  一、概述
  2017年是医药企业机遇与挑战并存的一年。随着国家医疗体制改革不断深入,医保目录调整更新、药品审评速度加快、仿制药一致性评价持续推进、两票制深入实施等政策对医药行业的影响逐步体现。
  2017上半年,医药工业增速较2016年略有回升。国家统计局规模以上工业企业数据显示,2017上半年医药制造业全行业的主营业务收入同比增长12.6%,利润同比增长15.9%。
  本报告期,本集团实现营业收入人民币4,274.76百万元,相比上年同期的人民币3,784.30百万元,同比增长12.96%;实现净利润人民币550.39百万元,相比上年同期的人民币427.47百万元,同比增长28.76%;实现归属于本公司股东的净利润人民币504.00百万元,相比上年同期的人民币409.06百万元,同比增长23.21%;若剔除非经常性损益项目收益,本公司2017年上半年主营业务实现的归属于本公司股东的净利润为人民币455.27百万元,相比上年同期的人民币363.84百万元,同比增长25.13%。
  2017上半年,本集团围绕“转型升级、规范发展”的管理方针,不断提高管控效率与规范治理水平,稳步推进各项业务,加快营销市场布局,取得了较好的成绩,主要工作情况如下:
  1、制剂药业务—强化合规营销,做深做透市场
  2017年上半年,本集团通过营造“宽环境,建机制,强责任,严考核”的销售工作氛围,完善营销体系建设,加强学术营销、终端推广,全力推进产品下沉和基层医疗机构队伍建设。
  主要工作如下:一是成立基层医疗销售部,促进二级以下医疗机构的产品覆盖与销售;二是在全国范围内开展重点品种低产医院增量活动,拉升低产医院的销售;三是完善全国物流体系布局,确保合规性及物流配送效率,缩短应收账款周转时间;四是非处方药细化营销考核,加强产品推广;五是推进新版国家医保工作,本次共有6个产品新纳入国家《医保目录》,同时积极应对省级医保目录增补工作;六是加强部分已上市品种的再评价、增加临床适应症等延伸开发。
  2、原料药及中间体业务—加强经营管理,力推营销及国际认证
  2017年初,本集团原发酵原料药事业部及珠海保税区丽珠合成制药有限公司正式合并运营,成立集团原料药事业部。原料药事业部始终坚持“保安环、抓质量、降成本”为工作主线,加强事业部对各下属企业的监管、督导职能。
  本报告期内,原料药事业部主要工作如下:一是制定重点品种攻关目标,加强项目成本考核,推进产品核心技术的升级改造,精进工艺,降低成本;二是推进研发体系建设,构建生物菌种选育和合成原料药研发两个研发队伍,加强特色优势产品的开发;三是完善销售市场布局,力争由低端市场向中等和高端市场的全方位覆盖,加大与国内外知名药企的战略合作;四是持续提升生产企业的安全、环保及质量水平,积极推进原料药国际注册认证力度。
  截至期末,本集团下属原料药生产企业通过国际认证现场检查品种10个,通过FDA现场检查品种5个,取得国际认证证书17个。
  3、精准医疗—加速布局,研发临床进展顺利
  本集团利用生物制剂与诊断试剂业务在精准医疗领域的协同优势效应,积极布局以“患者为中心”的个性化医疗领域业务,已初步形成“丽珠试剂+丽珠单抗+丽珠圣美+丽珠基因”的精准医疗的产业链布局。
  丽珠试剂:进一步加大自产产品的研发资金与人才投入,加快分子诊断、化学发光等在研产品的研发进度,优化研发管理流程,提升现有产品性能,积极推进营销体系改革与考核机制转变,完善自有营销团队建设。2017上半年,自产产品收入占比持续提高,其中传统传染病和呼吸道相关诊断试剂产品增长优势明显。
  丽珠单抗:报告期,继续完善人才梯队建设,引进6位海归人才,分别负责医学、质量、工艺、BD等部门。目前公司生物药领域共有12个项目在研,并已开展多个新药项目的筛选、评价、商务洽谈。
  丽珠圣美:报告期,丽珠圣美积极推进设备配件以及试剂的国产化工作。按照医疗器械GMP和GSP质量体系要求组织了全面的内审,对质量体系有序运行提供支持,并全力探索液态活检技术在中国医院市场的临床应用的可行模式,与北京协和、北大肿瘤等多家知名医院开展临床研究工作,同时在器械与试剂注册、市场准入与推广等多个方面研究探讨可行方案,已初步形成有效可执行的商业模式。
  丽珠基因:初步搭建了内部管理的运营体系,并完成了液态活检、蛋白免疫萤光、萤光PCR等技术平台的搭建,并积极推进第三方实验室相关资质认证与许可工作。
  4、生产—重质量、保安全、抓环保
  本集团继续强化生产过程中的质量控制,持续提升质量管理水平,促进企业质量管理体系健康运行。
  截至期末,本集团下属5家制剂企业30条生产线通过新版GMP认证,下属原料药企业13条生产线的25个品种通过新版GMP认证。本报告期内,本集团各企业未发生重大环保事故、安全事故和职业健康事故。本集团各企业基本完成环评等法规符合性工作,同时颁布了《丽珠集团EHS管理体系总体要求》等集团EHS管理制度,规范EHS管理行为,确保企业正常运行。
  5、管理及战略—强化内控管理,积极推进外延
  本报告期内,本集团秉持“转型升级、规范发展”的核心经营管理方针,不断完善和落实各项规章制度,加强公司内部控制,系统防范经营风险。主要工作包括:一是完善人事管理制度,对职能总部进行了职级体系重整以及薪资调整。二是优化行政管理平台和后勤服务平台,加强职能部门的工作管理。三是强化信息技术开发能力,优化资源分配,提高运营效率。四是优化集团资金管控,加强对二级企业财务工作的管理,提高集团资金使用效率和效益。五是持续申报科技项目及政府补助。
  在战略发展及投资方面,力争通过内生式与外延式相结合的方式强化公司核心竞争力。对内,本集团不断加强内部股权管理,提升运营效率。对外,加大投资力度,与知名国际投行及机构建立投资项目对接渠道,积极寻找符合公司发展战略的医药、医疗类潜在投资购并对象,进一步完善产业架构。

  二、报告期内公司从事的主要业务
  本报告期内,本集团的主营业务未发生变化,以医药产品的研发、生产及销售为主业,产品涵盖制剂产品、原料药和中间体及诊断试剂及设备,主要产品包括参芪扶正注射液、丽珠得乐(枸橼酸铋钾)系列产品、抗病毒颗粒、丽申宝(注射用尿促卵泡素)、乐宝得(注射用尿促性素)、壹丽安(艾普拉唑肠溶片)、丽福康(注射用伏立康唑)、丽康乐(注射用鼠神经生长因子)及贝依(注射用亮丙瑞林微球)等中西药制剂;美伐他汀、硫酸粘菌素、苯丙氨酸及头孢曲松钠等原料药和中间体;HIV抗体诊断试剂、肺炎支原体抗体诊断试剂(被动凝聚法)及梅素旋转体抗体诊断试剂(凝聚法)等诊断试剂产品。

  三、核心竞争力分析
  本报告期,本集团仍坚持以成为一家高端特色专科制药企业为发展目标,继续以“转型升级、规范发展”为核心经营理念,不断提高管控效率与规范治理水平,稳步推进各项业务。本报告期,本集团的核心竞争力未发生重大变化。主要体现在以下几个方面:
  1、多元化的产品结构和业务布局。
  本集团产品涵盖制剂产品、原料药和中间体、诊断试剂及设备等多个医药细分领域,并在抗肿瘤支持用药、辅助生殖用药、消化道用药、精神用药及神经用药等多个特色专科治疗领域方面形成了一定的市场优势。公司在持续加强单抗药物研发的同时,不断加快推进公司精准医疗业务布局。
  2、完善的营销体系与专业化的营销团队。
  本集团对营销工作实行精细化管理,不断完善营销体系建设,优化激励考核机制,加强学术营销、终端推广,通过优化资源配置,逐步构建了较为完善的营销体系;本集团各个领域营销团队及提供专业销售服务人员共计九千余人,营销网络覆盖全国各地,包括主要的医疗机构、连锁药店、疾控中心和卫生部门等终端。
  3、成熟的质量管理体系。
  本集团建立了涵盖产品生产质量、科研、销售等业务的立体化质量管理体系。报告期内,本集团持续提升质量管理水平,促使质量管理体系健康运行,有效地确保了本集团各领域产品的安全性和稳定性。
  4、强大的研发能力与国际化的研发理念。
  本集团在化学药、中药制剂、生物药以及诊断试剂等领域均有较强的研发能力及国际化的研发理念。
  通过积极引进国内外资深专家和创新型人才、不断加大研发投入、发展海外战略联盟等方式,围绕抗肿瘤、辅助生殖、消化、精神及神经等特色专科药的产品线布局,形成了较为清晰的产品研发管线,进而增强了本集团的研发竞争力。

  四、公司面临的风险和应对措施
  基于医药产业是我国重点发展的行业之一,医药产品关系到社会公众的健康和安全,近年来,中华人民共和国国家发展和改革委员会、中华人民共和国国家卫生和计划生育委员会、国家食品药品监督管理总局等有关部门陆续出台了药品审评审批改革、药价改革、医保控费、仿制药一致性评价、两票制等政策。随着政策的不断变革和持续更新,行业的环保及安全生产方面要求日趋严格,医药产业链条的各个环节,以及医药行业的投融资、市场供求关系、医药企业的经营模式、技术研发及产品售价等方面都受到较大影响。为此,公司通过早布局、早转型、早合规,积极应对医药行业的重大变化。
  目前,公司仍处于战略调整的重要阶段,已初步形成专科制剂药主导、生物药及精准医疗协同的市场布局。为更好的适应市场需求,公司将持续优化各领域业务布局,加强新产品的研发及创新力度,不断加大研发投入,完善市场准入工作,扩大销售规模,同时,提高生产质量的管理,规范安全环保生产。公司将通过转型升级,不断加强内部控制,规范发展,以建立自身的优势地位与核心竞争力。 收起▲